FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2337572018> ?p ?o ?g. }

• W2337572018 endingPage "92" @default.
• W2337572018 startingPage "83" @default.
• W2337572018 abstract "Advanced-stage prostate cancer usually metastasizes to bone and is untreatable due to poor biodistribution of intravenously administered anticancer drugs to bone. In this study, we modulated the surface charge/composition of biodegradable nanoparticles (NPs) to sustain their blood circulation time and made them small enough to extravasate through the openings of the bone's sinusoidal capillaries and thus localize into marrow. NPs with a neutral surface charge, achieved by modulating the NP surface-associated emulsifier composition, were more effective at localizing to bone marrow than NPs with a cationic or anionic surface charge. These small neutral NPs (~150nm vs. the more usual ~320nm) were also ~7-fold more effective in localizing in bone marrow than large NPs. We hypothesized that NPs that effectively localize to marrow could improve NP-mediated anticancer drug delivery to sites of bone metastasis, thereby inhibiting cancer progression and preventing bone loss. In a PC-3M-luc cell-induced osteolytic intraosseous model of prostate cancer, these small neutral NPs demonstrated greater accumulation in bone within metastatic sites than in normal contralateral bone as well as co-localization with the tumor mass in marrow. Significantly, a single-dose intravenous administration of these small neutral NPs loaded with paclitaxel (PTX-NPs), but not anionic PTX-NPs, slowed the progression of bone metastasis. In addition, neutral PTX-NPs prevented bone loss, whereas animals treated with the rapid-release drug formulation Cremophor EL (PTX-CrEL) or saline (control) showed >50% bone loss. Neutral PTX-NPs did not cause acute toxicity, whereas animals treated with PTX-CrEL experienced weight loss. These results indicate that NPs with appropriate physical and sustained drug-release characteristics could be explored to treat bone metastasis, a significant clinical issue in prostate and other cancers." @default.
• W2337572018 created "2016-06-24" @default.
• W2337572018 creator A5028558981 @default.
• W2337572018 creator A5056042575 @default.
• W2337572018 creator A5056118369 @default.
• W2337572018 creator A5071677506 @default.
• W2337572018 date "2016-06-01" @default.
• W2337572018 modified "2023-10-10" @default.
• W2337572018 title "Inhibition of bone loss with surface-modulated, drug-loaded nanoparticles in an intraosseous model of prostate cancer" @default.
• W2337572018 cites W111725520 @default.
• W2337572018 cites W1552589960 @default.
• W2337572018 cites W1606164928 @default.
• W2337572018 cites W1647414470 @default.
• W2337572018 cites W166400361 @default.
• W2337572018 cites W1938796902 @default.
• W2337572018 cites W1964513315 @default.
• W2337572018 cites W1965593909 @default.
• W2337572018 cites W1968252310 @default.
• W2337572018 cites W1968864885 @default.
• W2337572018 cites W1974892535 @default.
• W2337572018 cites W1977260466 @default.
• W2337572018 cites W1985421997 @default.
• W2337572018 cites W1990511776 @default.
• W2337572018 cites W1992075813 @default.
• W2337572018 cites W1992268549 @default.
• W2337572018 cites W1996255649 @default.
• W2337572018 cites W1997274211 @default.
• W2337572018 cites W1997921022 @default.
• W2337572018 cites W1999204999 @default.
• W2337572018 cites W1999592249 @default.
• W2337572018 cites W2000503805 @default.
• W2337572018 cites W2005838411 @default.
• W2337572018 cites W2013557720 @default.
• W2337572018 cites W2015141049 @default.
• W2337572018 cites W2018792579 @default.
• W2337572018 cites W2027525928 @default.
• W2337572018 cites W2029216847 @default.
• W2337572018 cites W2037048276 @default.
• W2337572018 cites W2044016557 @default.
• W2337572018 cites W2046851174 @default.
• W2337572018 cites W2050181086 @default.
• W2337572018 cites W2052609925 @default.
• W2337572018 cites W2053311966 @default.
• W2337572018 cites W2060721379 @default.
• W2337572018 cites W2066459637 @default.
• W2337572018 cites W2075140415 @default.
• W2337572018 cites W2078683291 @default.
• W2337572018 cites W2078725345 @default.
• W2337572018 cites W2079793032 @default.
• W2337572018 cites W2081365179 @default.
• W2337572018 cites W2082300336 @default.
• W2337572018 cites W2082511916 @default.
• W2337572018 cites W2087324367 @default.
• W2337572018 cites W2089220360 @default.
• W2337572018 cites W2094690600 @default.
• W2337572018 cites W2095248480 @default.
• W2337572018 cites W2096859743 @default.
• W2337572018 cites W2100207941 @default.
• W2337572018 cites W2101312385 @default.
• W2337572018 cites W2102857424 @default.
• W2337572018 cites W2113503879 @default.
• W2337572018 cites W2126598569 @default.
• W2337572018 cites W2132448724 @default.
• W2337572018 cites W2135187129 @default.
• W2337572018 cites W2135486162 @default.
• W2337572018 cites W2142939378 @default.
• W2337572018 cites W2144536924 @default.
• W2337572018 cites W2145716662 @default.
• W2337572018 cites W2147621051 @default.
• W2337572018 cites W2153046528 @default.
• W2337572018 cites W2156368993 @default.
• W2337572018 cites W2159622173 @default.
• W2337572018 cites W2161962336 @default.
• W2337572018 cites W2170220266 @default.
• W2337572018 cites W3111677647 @default.
• W2337572018 doi "https://doi.org/10.1016/j.jconrel.2016.04.019" @default.
• W2337572018 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4893970" @default.
• W2337572018 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27090164" @default.
• W2337572018 hasPublicationYear "2016" @default.
• W2337572018 type Work @default.
• W2337572018 sameAs 2337572018 @default.
• W2337572018 citedByCount "45" @default.
• W2337572018 countsByYear W23375720182016 @default.
• W2337572018 countsByYear W23375720182017 @default.
• W2337572018 countsByYear W23375720182018 @default.
• W2337572018 countsByYear W23375720182019 @default.
• W2337572018 countsByYear W23375720182020 @default.
• W2337572018 countsByYear W23375720182021 @default.
• W2337572018 countsByYear W23375720182022 @default.
• W2337572018 countsByYear W23375720182023 @default.
• W2337572018 crossrefType "journal-article" @default.
• W2337572018 hasAuthorship W2337572018A5028558981 @default.
• W2337572018 hasAuthorship W2337572018A5056042575 @default.
• W2337572018 hasAuthorship W2337572018A5056118369 @default.
• W2337572018 hasAuthorship W2337572018A5071677506 @default.
• W2337572018 hasBestOaLocation W23375720182 @default.
• W2337572018 hasConcept C121608353 @default.
• W2337572018 hasConcept C126322002 @default.

• next